Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis.
Olivia S CostaBridget O'DonnellBurcu VardarKhaled AbdelgawwadChristopher W BresciaNitesh SoodCraig I ColemanPublished in: Current medical research and opinion (2021)
Rivaroxaban was associated with reduced incidence rates of kidney and limb complications, and death in NVAF patients with type 2 diabetes compared to warfarin. ClinicalTrials.gov Identifier: NCT04509193.
Keyphrases
- atrial fibrillation
- electronic health record
- oral anticoagulants
- direct oral anticoagulants
- risk factors
- type diabetes
- catheter ablation
- left atrial
- left atrial appendage
- venous thromboembolism
- clinical decision support
- heart failure
- percutaneous coronary intervention
- cardiovascular disease
- adverse drug
- glycemic control
- insulin resistance
- metabolic syndrome
- weight loss
- pulmonary embolism
- coronary artery disease
- acute coronary syndrome
- data analysis